Content area
Full text
Int J Hematol (2011) 94:583584 DOI 10.1007/s12185-011-0973-x
LETTER TO THE EDITOR
Cytokine proles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide
Yasuyoshi Morita Takahiro Shimada Terufumi Yamaguchi Shinya Rai
Chikara Hirase Masakatsu Emoto Kentaro Serizawa Yasuhiro Taniguchi
Mayuko Ojima Yoichi Tatsumi Takashi Ashida Itaru Matsumura
Received: 16 September 2011 / Revised: 10 November 2011 / Accepted: 10 November 2011 / Published online: 30 November 2011 The Japanese Society of Hematology 2011
Lenalidomide plays a central role in the treatment of multiple myeloma (MM). Ozaki et al. [1] very recently reported two cases that had developed inammatory reactions to lenalidomide. We also experienced three similar cases among eight cases treated in our hospital from August 2010 to July 2011 (Table 1).
Case 1 received lenalidomide (10 mg/day on days 121) plus dexamethasone (20 mg on days 14) on a 28-day cycle. On day 7 at cycle 1, the patient developed high fever without apparent infection. After tapering the dose of lenalidomide to 5 mg/day without administration of antibiotics, his fever slowly receded.
Case 2 received lenalidomide monotherapy (15 mg/day on days 121) on a 28-day cycle. On day 14 at cycle 1, the patient developed mild fever without focus of infection. We reduced the dose to 10 mg/day. The fever subsequently receded.
Case 3 received lenalidomide (15 mg/day on days 121) plus dexamethasone (8 mg on days 14) on a 28-day cycle. On day 6 at cycle 1, the patient developed high fever without focus of infection. Five days after stopping lena-lidomide, the fever receded.
Cases 48 received lenalidomide (15 mg on days 121) plus dexamethasone therapy (20 mg/day on...